Form 4: PROCEPT CFO Kevin Waters Earns 3,532 Shares

PROCEPT BioRobotics Corp's EVP and CFO, Kevin Waters, was deemed to have earned 3,532 shares of common stock following the certification of performance criteria for previously granted performance stock units.

Summary

• Kevin Waters, EVP, CFO of PROCEPT BioRobotics Corp, was deemed to have earned 3,532 shares of common stock.
• These shares are from previously granted performance stock units (PSUs).
• The vesting of these PSUs was contingent on the Issuer's achievement of pre-determined performance criteria.
• The Compensation Committee certified the achievement of these criteria on February 19, 2026.
• The earned PSUs will vest on March 5, 2026.
• Following this transaction, Kevin Waters beneficially owns 111,523 shares of common stock directly.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive indicator, as it confirms the company met specific performance criteria, leading to executive equity vesting, which suggests operational success in the past period.

Positives

• The company's Compensation Committee certified the achievement of pre-determined performance criteria, indicating the company met specific operational or financial goals.
• The vesting of performance stock units aligns management incentives with shareholder value creation.

Future Outlook

The filing indicates future vesting of shares on March 5, 2026, based on past performance criteria being met. It does not provide broader forward-looking statements about company performance.

Industry Context

StockSavvy.ai notes that the vesting of performance-based equity awards is a common practice in the medical device and robotics industry, aligning executive incentives with long-term company performance and shareholder interests. This particular transaction reflects the achievement of specific internal performance metrics by PROCEPT BioRobotics.

Comparison to Industry Standards

• The use of Performance Stock Units (PSUs) for executive compensation is a standard practice across many industries, including medical technology, to link executive pay to company performance.
• Companies like Intuitive Surgical (ISRG) and Stryker (SYK) also utilize performance-based equity awards to incentivize their leadership teams, often tied to revenue growth, profitability, or product development milestones.
• The specific performance criteria achieved by PROCEPT BioRobotics are not detailed in this filing, making a direct comparison of the results difficult, but the mechanism of compensation is consistent with industry best practices.

Stakeholder Impact

• Shareholders: The achievement of performance criteria for executive compensation suggests positive operational performance, which could be beneficial for shareholder value.
• Employees: No direct impact mentioned, but successful company performance can positively influence employee morale and future opportunities.

Next Steps

• The 3,532 earned PSUs will vest on March 5, 2026.

Key Dates

Recommendation

This Form 4 filing reports a routine insider transaction related to the vesting of performance stock units, indicating the company met its internal performance criteria. While positive, it does not provide new material information that would significantly alter the investment thesis for PROCEPT BioRobotics. Therefore, a 'hold' recommendation is appropriate, maintaining current positions while awaiting more comprehensive financial updates.

Keywords

PROCEPT BioRobotics, PRCT, Kevin Waters, Form 4, Insider Transaction, Performance Stock Units, PSUs, Executive Compensation, Stock Vesting